RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.


RTI International Makes Investment in Seven Bridges Genomics

RESEARCH TRIANGLE PARK, N.C. — RTI International, a leading research institute, today announced an investment in Seven Bridges Genomics, the industry-leading bioinformatics ecosystem provider, to help facilitate scientific discovery and speed the path from raw experimental data to new healthcare treatments and diagnostics.  RTI’s investment joins the previously announced Seven Bridges Series C financing round along with a strategic life sciences investor.

“We are pleased to support the growth of biomedical technology solutions that advance public and private healthcare research driven by large multi-omic datasets”, said Matt Jenkins, vice president and head of corporate development and private investments at RTI.  “Seven Bridges enables bioinformatics researchers at leading academic, biotechnology, government, and pharmaceutical entities to accelerate scientific discovery. The company’s focus is well aligned with RTI’s portfolio of science-driven solutions that improve the human condition.” 

Seven Bridges enables researchers to extract meaningful insights from vast quantities of genomic and phenotypic data to advance precision medicine. The investment from RTI will help fuel the innovation of new products and help scale the organization to support clients’ use of multi-omics data in their research. 

RTI’s investment in Seven Bridges adds to its investment portfolio spanning domains including clinical research technology, precision medicine, healthcare analytics, patient engagement solutions, population health, and diagnostic testing. 

“We welcome RTI as an investor with their market, technical, and scientific expertise and leadership,” said William Moss, chief executive officer of Seven Bridges. “As the availability of multi-omic data grows exponentially, it is essential that clinical researchers and drug developers have access to robust tools for integrating, analyzing and applying that data to discover cures. RTI’s investment will help ensure that the Seven Bridges data ecosystem grows and evolves to handle diverse, global datasets, including population studies at the 1M+ participant scale.”

About Seven Bridges
Seven Bridges enables researchers to extract meaningful insights from genomic and phenotypic data in order to advance precision medicine. The Seven Bridges Ecosystem consists of a compliant analytic platform, intelligently curated content, transformative algorithms, unprecedented access to federated data sets, and expert on-demand professional services. This holistic approach to bioinformatics is enabling researchers — at the world’s leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical entities — to increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and even turn a failing clinical trial around while also reducing computational workflow times and data storage costs. To learn more, visit sevenbridges.com or follow us on LinkedIn and Twitter.